STAAR Surgical Q1 net sales up 5% to $77.4M; net loss $0.07ps; raises FY24 EBITDA outlook

STAAR SURGICAL CO

2024-Q1 EPS reported -$0.07 revenue$77,356,000

Net sales $77.4M (+5% YoY; +7% constant currency); ICL sales +9% on +2% units.
Net loss $3.3M ($0.07 loss per share) vs net income $2.7M ($0.05) a year ago; Adjusted EBITDA $5.3M ($0.11) vs $10.0M ($0.20).
U.S. sales $5M, up 15% YoY and 21% sequentially; record cash $252.1M.
FY2024 net sales outlook reiterated at $335-$340M; Adjusted EBITDA guidance raised to ~$39M ($0.75 per share) from ~$36M.
APAC sales +9% (China +10%); EMEA +11%; largest-ever U.S. practice commitment to EVO ICL announced.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STAAR SURGICAL CO reported first quarter ended March 29, 2024 results: revenue $77.4 million, net income Net loss of $3.3 million or $0.07 loss per share, EPS $0.07 loss per share. Guidance reaffirmed.

Period: first quarter ended March 29, 2024
Revenue: $77.4 million
Net income: Net loss of $3.3 million or $0.07 loss per share
EPS: $0.07 loss per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

(EVO ICLTM) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024. First Quarter 2024 Overview • Net sales up 5% to $77.4 million and up 7% in constant currency • ICL sales up 9% and units up 2% • Gross margin at 78.9% vs. 78.3% year ago • Net loss of $3.3 million or $0.07 loss per share vs. net income of

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0000950170-24-054454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.